Ascentage Pharma Group International (AAPG)

Market Cap	2.00B +17.9%
Revenue (ttm)	82.08M -41.5%
Net Income	-177.68M
EPS	-0.50
Shares Out	370.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,314
Open	21.90
Previous Close	21.70
Day's Range	21.32 - 21.90
52-Week Range	19.11 - 48.45
Beta	0.72
Analysts	Strong Buy
Price Target	48.40 (+125.12%)
Earnings Date	May 20, 2026

About AAPG

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 24, 2025
• Employees: 767
• Stock Exchange: NASDAQ
• Ticker Symbol: AAPG
• Website: https://www.ascentage.cn

Financial Performance

In 2025, AAPG's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 5 analysts, the average rating for AAPG stock is "Strong Buy." The 12-month stock price target is $48.4, which is an increase of 125.12% from the latest price.

Price Target

$48.4

(125.12% upside)

Analyst Consensus: Strong Buy